Welcome to our dedicated page for Zentek Ltd. news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek has been granted a second patent by the Canadian Intellectual Property Office for its Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites, recognized as a broad-spectrum antimicrobial agent.
The patent includes 64 successful claims and covers the compound's use against bacteria, fungi, and viruses in various forms such as liquid, powder, and ointments. Zentek has also applied for this patent with the U.S. Patent and Trademark Office.
GO-Ag+ has shown higher cytotoxicity against bacteria than human cells and is being studied for its effectiveness in preventing and eliminating biofilms, a significant challenge in wound care and medical devices. The patent supports further development of GO-Ag+-based products for medical and veterinary markets.
CEO Greg Fenton emphasized that this milestone is important for Zentek's intellectual property commercialization strategy and aims to maximize shareholder value.
Zentek has signed a distribution agreement with DCL Supply for ZenGUARD Enhanced Air Filters, effective from March 19th, 2024, with an initial term of one year, automatically renewing annually unless terminated with 90 days' notice. These filters aim to improve indoor air quality without significantly increasing energy consumption or emissions. The agreement is pending Health Canada's registration under the Pest Control Products Act, allowing DCL Supply to distribute the filters across Canada upon approval.
DCL Supply, a reputable HVAC distributor with over 40 years of experience, will leverage its extensive network to deliver these innovative solutions. This partnership aims to address the growing need for efficient air filtration in industrial, commercial, and institutional settings, potentially reducing maintenance costs and improving health outcomes.
Zentek completed a case study on HVAC Total Cost of Ownership Savings for the City of Toronto, showcasing the benefits of using MERV 9A filters over MERV 13 filters. The study revealed annual cost savings of over $40 million, reduced carbon emissions, waste, and energy consumption. Zentek aims to provide property managers with a cost-effective, environmentally friendly solution to control infectious aerosols and keep people safe.
Zentek announces that its subsidiary, Triera Biosciences , has achieved positive results against avian influenza (H5N1) using multivalent aptamer technology. The development of a prophylaxis and therapeutic for highly pathogenic avian influenza has been prioritized, with promising initial test results. The binding affinity of the influenza aptamer is superior to that of the aptamer used for SARS-CoV-2, showing improved protection in animal models. The World Health Organization has labeled the current H5N1 outbreak as an 'enormous concern,' prompting governments worldwide to focus on combating the virus. Triera has filed a provisional patent on the influenza virus-targeting aptamer, aiming to develop assets to prevent further transmission of H5N1 and other infectious diseases.
Zentek announces board and management changes with the resignation of Dr. Francis Dubé as COO and Brian Bosse as a director, who has been appointed to the advisory board. The Company granted Mr. Bosse stock options for 40,000 shares at $1.42 per share.
FAQ
What is the current stock price of Zentek Ltd. (ZTEK)?
What is the market cap of Zentek Ltd. (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
